CORONA Remedies Limited has clarified that the recent movement in the volume of its shares is purely market-driven. The company confirmed it is fully compliant with all disclosure obligations and currently has no undisclosed or price-sensitive information, impending announcements, or corporate actions that require sharing with the exchange. For retail...
CORONA Remedies reports Q1 FY27 revenue up 21.9% to ₹422.4 Cr and PAT up 30.1% to ₹60.1 Cr. Company is the fastest growing among top 30 IPMs and ranks 26th. New EU-GMP female hormone plant operational.
CORONA Remedies commenced commercial production at its EU-GMP approved Women's Hormone facility. The state-of-the-art plant strengthens manufacturing capabilities for domestic and international markets, expected to boost in-house hormone manufacturing capacity by 20%.
Corona Remedies secured EU-GMP certifications for its Hormone manufacturing facility and renewed approval for its Oral Solid Dosage facility in Ahmedabad. This enhances global quality standards and market expansion potential.
CORONA Remedies announced strong FY26 results: Revenue up 17.3%, PAT up 33.4%. Acquired WOKADINE for ₹648 Cr, relaunched key brands, and entered new markets with EAEU-GMP certification.
